Owkin uses federated learning to train AI models on hospital data without moving it — for biomarker discovery, drug development, and patient stratification. Strategic partnerships with Sanofi, BMS. Paris + NYC HQ. Founded by Thomas Clozel and Gilles Wainrib.
Builder’s Brief
Owkin is a healthcare tool on Falcoscan. Federated learning for biopharma. Falcoscan rates Owkin with an Opportunity score of 75/100, a Saturation score of 12/100, and a Wrapper-risk score of 5/100. Market signal: rising. Owkin is founded in 2016, currently at Series_d_plus stage. Pricing: Paid.
Market position · Healthcare
How Owkin compares in Healthcare
Owkin's opportunity score of 75 ranks #123 of 137 live Healthcare tools on Falcoscan, 6.8 points below the category average of 81.8. Its saturation score is 12/100, against a category average of 11. 75 of the 137 live Healthcare tools carry a hot signal, and Falcoscan has recorded 8 shutdowns in the category.
The top-rated live Healthcare tools on Falcoscan, other than Owkin, are DeepMind AlphaFold, Nuance DAX Copilot, Viz.ai AI Stroke Response, Tempus AI Diagnostics, and Viz.ai Stroke AI.
Is Owkin still operating?
Yes. Falcoscan's operating checks list Owkin as active.
Where is Owkin based?
Owkin is headquartered in Paris, France.
Does Owkin have an API?
Falcoscan's records show no public API for Owkin.
Who is Owkin for?
Owkin is built for enterprises, pharma, and healthcare providers.